Bosentan added to sildenafil therapy in patients with pulmonary
... known to be involved in the pathogenesis of PAH and therapies that target these pathways are available [1–3]. Combining agents that target more than one pathway is an attractive option for the treatment of PAH and may offer additional long-term benefits compared with monotherapy [4, 5]. The proceedi ...
... known to be involved in the pathogenesis of PAH and therapies that target these pathways are available [1–3]. Combining agents that target more than one pathway is an attractive option for the treatment of PAH and may offer additional long-term benefits compared with monotherapy [4, 5]. The proceedi ...
- European Medical Journal
... misdiagnosed, which is critical given that disease progression can be unpredictable, with liver failure and/or accelerated atherosclerosis potentially contributing to early mortality. However, a definitive diagnosis of LAL D can be made using a LAL enzyme-based biochemical test, thereby allowing for ...
... misdiagnosed, which is critical given that disease progression can be unpredictable, with liver failure and/or accelerated atherosclerosis potentially contributing to early mortality. However, a definitive diagnosis of LAL D can be made using a LAL enzyme-based biochemical test, thereby allowing for ...
Optinate 75 mg film-coated tablet ENG SmPC
... emptying e.g. stricture or achalasia. In patients who are unable to stay in the upright position for at least 30 minutes after taking the tablet. If risedronate is given to patients with active or recent oesophageal or upper gastrointestinal problems (including known Barrett’s oesophagus). Prescribe ...
... emptying e.g. stricture or achalasia. In patients who are unable to stay in the upright position for at least 30 minutes after taking the tablet. If risedronate is given to patients with active or recent oesophageal or upper gastrointestinal problems (including known Barrett’s oesophagus). Prescribe ...
BENIGN ESOPHAGEAL DISEASES
... Impedance returns to baseline once bolus is cleared by a contraction Can be performed in combination with manometry or pH testing When combined with manometry, bolus transit data can add a functional analysis to manometrically recorded ...
... Impedance returns to baseline once bolus is cleared by a contraction Can be performed in combination with manometry or pH testing When combined with manometry, bolus transit data can add a functional analysis to manometrically recorded ...
Avestra 75 mg film-coated tablet ENG SmPC
... emptying e.g. stricture or achalasia. In patients who are unable to stay in the upright position for at least 30 minutes after taking the tablet. If risedronate is given to patients with active or recent oesophageal or upper gastrointestinal problems (including known Barrett’s oesophagus). Prescribe ...
... emptying e.g. stricture or achalasia. In patients who are unable to stay in the upright position for at least 30 minutes after taking the tablet. If risedronate is given to patients with active or recent oesophageal or upper gastrointestinal problems (including known Barrett’s oesophagus). Prescribe ...
Predicting anticoagulant-related bleeding in patients with venous thromboembolism: a clinically oriented review
... UFH. The results have been summarised in a meta-analysis with pooled data from 7124 patients: major haemorrhage occurred in 41 (1.2%) out of 3500 patients treated with LMWH compared with 73 (2.0%) out of 3624 patients treated with UFH (OR 0.57, 95% CI 0.39–0.83), thus suggesting that LMWH may reduce ...
... UFH. The results have been summarised in a meta-analysis with pooled data from 7124 patients: major haemorrhage occurred in 41 (1.2%) out of 3500 patients treated with LMWH compared with 73 (2.0%) out of 3624 patients treated with UFH (OR 0.57, 95% CI 0.39–0.83), thus suggesting that LMWH may reduce ...
Maintenance infliximab for Crohn`s disease: the ACCENT I
... Crohn’s disease is a chronic inflammatory disorder of the gastrointestinal tract. Although mild disease can be treated with 5-aminosalicylates, many patients eventually require corticosteroids to control symptoms.1 Once started, acute and in particular chronic use of corticosteroids is associated wi ...
... Crohn’s disease is a chronic inflammatory disorder of the gastrointestinal tract. Although mild disease can be treated with 5-aminosalicylates, many patients eventually require corticosteroids to control symptoms.1 Once started, acute and in particular chronic use of corticosteroids is associated wi ...
Document
... Secondary leukemia, with or without a preleukemic phase, has been reported in patients treated with anthracyclines, including idarubicin. Secondary leukemia is more common when such drugs are given in combination with DNA damaging antineoplastic agents, when patients have been heavily pretreated wit ...
... Secondary leukemia, with or without a preleukemic phase, has been reported in patients treated with anthracyclines, including idarubicin. Secondary leukemia is more common when such drugs are given in combination with DNA damaging antineoplastic agents, when patients have been heavily pretreated wit ...
Extract from the Clinical Evaluation Report for Bortezomib
... all B-NHL and occurs most often in older people (median age at diagnosis 65 years). Although the disease can follow a variable course, most patients are diagnosed with Stage III or IV disease and have both bone marrow and extranodal disease. The treatment of MCL is generally unsatisfactory and it is ...
... all B-NHL and occurs most often in older people (median age at diagnosis 65 years). Although the disease can follow a variable course, most patients are diagnosed with Stage III or IV disease and have both bone marrow and extranodal disease. The treatment of MCL is generally unsatisfactory and it is ...
REVIEWS
... antibodies and drugs are more effective against fungal infections than when either therapy is used alone15,20,23. Consequently, antibody-based therapies could easily be incorporated into existing treatment protocols; however, demonstrating the advantages of combination therapy in rigorous clinical t ...
... antibodies and drugs are more effective against fungal infections than when either therapy is used alone15,20,23. Consequently, antibody-based therapies could easily be incorporated into existing treatment protocols; however, demonstrating the advantages of combination therapy in rigorous clinical t ...
PRODUCT MONOGRAPH MabCampath
... known to occur in B-CLL patients (Bower et al., 1997, Neurology). Progressive multifocal leukoencephalopathy has been reported in patients with B-CLL with or without treatment with MabCampath. The reported frequency of PML in B-CLL patients treated with MabCampath is no greater than the reported bac ...
... known to occur in B-CLL patients (Bower et al., 1997, Neurology). Progressive multifocal leukoencephalopathy has been reported in patients with B-CLL with or without treatment with MabCampath. The reported frequency of PML in B-CLL patients treated with MabCampath is no greater than the reported bac ...
Review of cough and cold medicines in children: Tabulated
... with bronchitis, although they may be of benefit to this population in other ways. Peripheral and central antitussive agents can be useful in patients with chronic bronchitis, but can have little efficacy in patients with cough due to upper respiratory infection. Some protussive agents are effective ...
... with bronchitis, although they may be of benefit to this population in other ways. Peripheral and central antitussive agents can be useful in patients with chronic bronchitis, but can have little efficacy in patients with cough due to upper respiratory infection. Some protussive agents are effective ...
A Guide to Clinical Decision-Making: The PSAP
... Clinicians continue to find the information in the Pharmacotherapy Self-Assessment Program (PSAP) modules not only a superb educational resource, but also a valuable patient care resource, replete with up-to-date information. The algorithms particularly can be used by clinicians as a quick reference ...
... Clinicians continue to find the information in the Pharmacotherapy Self-Assessment Program (PSAP) modules not only a superb educational resource, but also a valuable patient care resource, replete with up-to-date information. The algorithms particularly can be used by clinicians as a quick reference ...
Rivastigmine Patch
... serious adverse events between patients treated with the patch, the capsule or placebo. Although less nausea and vomiting were observed with the patch than the oral capsule, it is uncertain whether this difference was a result of lower drug concentrations being delivered by the patch. ...
... serious adverse events between patients treated with the patch, the capsule or placebo. Although less nausea and vomiting were observed with the patch than the oral capsule, it is uncertain whether this difference was a result of lower drug concentrations being delivered by the patch. ...
Rajiv Gandhi University of Health Sciences, Bangalore, Karnataka
... Osteoarthritis has a variable progression with some patients rapidly progressing to disability, where as others may continue to have mild symptoms. Currently, osteoarthritis has no cure but the disease can be palliated.7 Thus treated should be tailored to fit the individual patient, clinical severit ...
... Osteoarthritis has a variable progression with some patients rapidly progressing to disability, where as others may continue to have mild symptoms. Currently, osteoarthritis has no cure but the disease can be palliated.7 Thus treated should be tailored to fit the individual patient, clinical severit ...
Medications for Managing COPD in Hospice Patients
... Oral drug for severe COPD Only for : COPD w/ chronic bronchitis & history of exacerbations Not for: COPD characterized by emphysema Dose: 500mcg PO once daily routinely – to reduce exacerbations Mech. of action: phosphodiesterase inhibitor (antiinflammatory) Concern: High potential for side effects ...
... Oral drug for severe COPD Only for : COPD w/ chronic bronchitis & history of exacerbations Not for: COPD characterized by emphysema Dose: 500mcg PO once daily routinely – to reduce exacerbations Mech. of action: phosphodiesterase inhibitor (antiinflammatory) Concern: High potential for side effects ...
The Potential Role of Therapeutic Drug Monitoring in the Treatment
... – Ratings for specific conditions are as follows: Pregnancy: AIa Chronic HBV coinfection when HBV treatment is indicated: (AIIa) HCV coinfection: CIII (however, coinfection with CD4 cell count >500/µL may delay ART until after completion of HCV treatment) Age older than 60 years: BIIa HlV- ...
... – Ratings for specific conditions are as follows: Pregnancy: AIa Chronic HBV coinfection when HBV treatment is indicated: (AIIa) HCV coinfection: CIII (however, coinfection with CD4 cell count >500/µL may delay ART until after completion of HCV treatment) Age older than 60 years: BIIa HlV- ...
BEXXAR therapy
... stimulating hormone (TSH) levels should be monitored before treatment with BEXXAR®, and then every 6 months for the first 2 years, and annually thereafter. Serum creatinine levels should be measured prior to administration of BEXXAR®. Administration of BEXXAR® may result in the development of human ...
... stimulating hormone (TSH) levels should be monitored before treatment with BEXXAR®, and then every 6 months for the first 2 years, and annually thereafter. Serum creatinine levels should be measured prior to administration of BEXXAR®. Administration of BEXXAR® may result in the development of human ...
Goals and Objectives of Training in Clinical Neurophysiology
... o The identification and treatment of common neuromuscular disorders in children and adults o The inpatient and outpatient evaluation of new onset neuropathy including obtaining an appropriate history, physical examination, and the use of ancillary testing. o The inpatient and outpatient evaluation ...
... o The identification and treatment of common neuromuscular disorders in children and adults o The inpatient and outpatient evaluation of new onset neuropathy including obtaining an appropriate history, physical examination, and the use of ancillary testing. o The inpatient and outpatient evaluation ...
7 Drug-resistant tuberculosis and HIV
... number of TB cases notified in Swaziland has increased 6 fold over the last 15 years and is among the highest in the world. Although Swaziland is not listed among the 9 Southern High TB Burden countries, nor among the 9 African High TB Burden countries, the highest TB incidence in the world is repor ...
... number of TB cases notified in Swaziland has increased 6 fold over the last 15 years and is among the highest in the world. Although Swaziland is not listed among the 9 Southern High TB Burden countries, nor among the 9 African High TB Burden countries, the highest TB incidence in the world is repor ...
Address Line One
... It is recommended that patients taking Meridia make an appointment with their doctor at the next convenient time to discuss alternatives for losing weight. Patients who wish to stop treatment before seeing their doctor can do so at any time. Patient and physician questions can be answered through th ...
... It is recommended that patients taking Meridia make an appointment with their doctor at the next convenient time to discuss alternatives for losing weight. Patients who wish to stop treatment before seeing their doctor can do so at any time. Patient and physician questions can be answered through th ...
Ischemic Stroke
... • As always, get the compete story of the HPI: onset, duration, symptoms, severity, modifying factors, etc. This is often neglected and is the most important evaluation to make the correct diagnosis. • Note if the onset on symptoms was less than three hours ago. If it was an ischemic stroke, and the ...
... • As always, get the compete story of the HPI: onset, duration, symptoms, severity, modifying factors, etc. This is often neglected and is the most important evaluation to make the correct diagnosis. • Note if the onset on symptoms was less than three hours ago. If it was an ischemic stroke, and the ...
Pulmicort Respules
... receptor affinity studies, the 22R form was two times as active as the 22S epimer. In vitro studies indicated that the two forms of budesonide do not interconvert. The precise mechanism of corticosteroid actions on inflammation in asthma is not well known. Inflammation is an important component in t ...
... receptor affinity studies, the 22R form was two times as active as the 22S epimer. In vitro studies indicated that the two forms of budesonide do not interconvert. The precise mechanism of corticosteroid actions on inflammation in asthma is not well known. Inflammation is an important component in t ...
Management of multiple sclerosis
Several therapies for multiple sclerosis (MS) exist, although there is no known cure. Multiple sclerosis is a chronic inflammatory demyelinating disease that affects the central nervous system (CNS).The most common initial course of the disease is the relapsing-remitting subtype, which is characterized by unpredictable attacks (relapses) followed by periods of relative remission with no new signs of disease activity. After some years, many of the people who have this subtype begin to experience neurologic decline without acute relapses. When this happens it is called secondary progressive multiple sclerosis. Other, less common, courses of the disease are the primary progressive (decline from the beginning without attacks) and the progressive-relapsing (steady neurologic decline and superimposed attacks). Different therapies are used for patients experiencing acute attacks, for patients who have the relapsing-remitting subtype, for patients who have the progressive subtypes, for patients without a diagnosis of MS who have a demyelinating event, and for managing the various consequences of MS.The primary aims of therapy are returning function after an attack, preventing new attacks, and preventing disability. As with any medical treatment, medications used in the management of MS may have several adverse effects, and many possible therapies are still under investigation. At the same time different alternative treatments are pursued by many patients, despite the paucity of supporting, comparable, replicated scientific study.This article focuses on therapies for standard MS; borderline forms of MS have particular treatments that are excluded.